Hashtag
The Times

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

  • Brings over 20 years of clinical experience, including management of Phase 1-2 clinical trials in a variety of indications such as ophthalmology
  • Will oversee all R&D operations with focus on clinical development and operations

Kensington, MD, USA - EQS Newswire - 25 October 2023 - Galimedix Therapeutics, Inc.

("Galimedix"), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the appointment of Luciana Summo, PhD, as Vice President, R&D Operations. In this newly created position, she will oversee all activities related to R&D operations, with an emphasis on clinical development and operations. This includes spearheading the design, planning, and execution of clinical trials. Dr. Summo reports to Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer.

"We are delighted to welcome Luciana to Galimedix," said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman. "She brings strong experience setting up and running clinical trials and ensuring that all of the proper support structures are put in place. As we move our lead product candidate, GAL-101, into Phase 2 testing for the treatment of dry age-related macular degeneration, her skill set is the perfect fit for this next stage in our development. Luciana will play a pivotal role in defining Galimedix's overall R&D strategy and driving our R&D initiatives forward. All of us very much look forward to working with her as we contribute to advancing innovative healthcare solutions that have the potential to improve the lives of patients."

Dr. Summo has over 20 years of experience in clinical development and operations, including the management of Phase 1-2 clinical trials in several indications such as ophthalmology, cardiology, and oncology. Prior to joining Galimedix, she worked in positions of increasing responsibility in the clinical departments at OMEICOS Therapeutics GmbH, NOXXON Pharma AG, and Berlin-Chemie AG/ Menarini Group. She is well versed in setting up and overseeing clinical trials on a global scale and has played a key role in transitioning programs from pre-clinical to clinical stage. She has experience with the entire spectrum of activities related to R&D operations, with a special emphasis on clinical development and clinical operations, including also quality management and CMC. She works closely with cross-functional teams, including CROs, scientists, clinicians, regulatory affairs specialists, and different stakeholders, to ensure that trials are conducted in accordance with rigorous scientific standards and regulatory guidelines. Dr. Summo has experience in submitting Clinical Trial Applications (CTAs) in Europe and Investigational New Drug (IND) applications in the US and prepared for and participated in pre-IND meetings with the US Food and Drug Administration (FDA), as well as regulatory agency meetings in Europe. She also has set up from scratch and run a clinical operations department.

Luciana Summo, PhD, Vice President, R&D Operations, added: "I am truly excited to be joining Galimedix at this important point in the Company's growth. The programs in ophthalmology and Alzheimer's disease have the potential to change the treatment paradigm, and I look forward to working with the rest of the team to bring them forward in the clinic."
Hashtag: #Galimedix

The issuer is solely responsible for the content of this announcement.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix's groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer's disease - Galimedix's initial areas of focus. The Company's approach targets toxic Aβ oligomers and protofibrils. Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer's disease. Compelling pre-clinical data support the potential of Galimedix's product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned.

Business News

How Condition Based Monitoring Supports Better Equipment Maintenance

Moving Beyond Fixed Maintenance Intervals Condition based monitoring gives maintenance teams a way to assess equipment according to its actual operating condition rather than relying only on predet...

Hashtag.net.au - avatar Hashtag.net.au

Choosing Reliable Movers Melbourne Households Can Depend On

Moving home involves much more than transporting furniture from one address to another. The right movers Melbourne households choose can help organise the practical details, from collection and transp...

Hashtag.net.au - avatar Hashtag.net.au

Google's New Online Estimates Could Be Bad for Businesses and Customers

Google's AI-powered pricing feature allows users to request pricing information from businesses, making it easier to compare estimates. While this may save customers time, it also raises concerns abou...

Hashtag.net.au - avatar Hashtag.net.au

From Warehouse to Hotspot: Why Brisbane's Breweries, Gyms and Cafés Love Industrial Epoxy Flooring

Walk through Newstead, Teneriffe, West End or Fortitude Valley and you'll notice a pattern. Old warehouses, workshops and factories are being transformed into craft breweries, specialty cafés, bouti...

Hashtag.net.au - avatar Hashtag.net.au

Custom Packaging Ideas to Discuss With a Cardboard Box Manufacturer

Build Packaging Around the Way Products Move Packaging has to work through the full movement of a product, from packing and storage to delivery or retail display. A cardboard box manufacturer can h...

Hashtag.net.au - avatar Hashtag.net.au

How Disability Service Providers Can Support Individual Goals

Disability service providers can play an important role in helping people access practical assistance while maintaining choice, independence and participation in everyday life. The most useful suppo...

Hashtag.net.au - avatar Hashtag.net.au

Health & Wellness

Looking After a Hearing Aid: The Small Daily Habits That Matter

Hashtag.net.au - avatar Hashtag.net.au

A hearing aid is a small electronic device worn close to skin, sweat and earwax, and it needs regular care to keep working as it should. Most of that care is simple and takes only a minute or two, b...

What to Look for When Choosing a Dental Clinic Melbourne Patients Can Rely On

Hashtag.net.au - avatar Hashtag.net.au

Look at the Range of Dental Care Available Choosing a dental practice is easier when patients can access different types of care in one place. A dental clinic Melbourne patients visit may provide gen...

What Do Clinical Teams Need from Their Surgical Supply Partners?

Hashtag.net.au - avatar Hashtag.net.au

In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...

hacklink esim usazlibraryzlibrarySahabetuk casinos not on gamstopgrandpashabet girişseo ajansıyurtdışı turseo danışmanlığıjojobetgrandpashabetviagra 100 mg fiyatjojobetcasibomjojobetjojobettaraftarium24taraftarium24extrabet